Physician profile
Vedat Obuz
NPI 1255385233
$1,420.32
in general payments reported to CMS, 2019-2025
24 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.94 · 2020: $132 · 2021: $238 · 2022: $142 · 2023: $232 · 2024: $379 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $205.81 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Pharming Healthcare, INC. | $139.22 | 2019-2025 | Ruconest |
| Lilly USA, LLC | $130.87 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $124.73 | 2023-2024 | |
| Novo Nordisk INC | $110.58 | 2021-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $109.20 | 2019-2024 | M-M-R II, Varivax, Gardasil 9 |
| Biocryst US Sales Co., LLC | $95.57 | 2023-2024 | Orladeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.16 | 2020-2022 | |
| Glaxosmithkline, LLC. | $48.64 | 2021-2025 | Bexsero, Rotarix, Pediarix |
| Csl Behring | $46.41 | 2019-2025 | Haegarda |
| Kowa Pharmaceuticals America, INC. | $43.76 | 2024 | Zoryve |
| Amgen INC. | $40.48 | 2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $40.28 | 2019 | |
| Almatica Pharma LLC | $39.82 | 2022 | |
| Xeris Pharmaceuticals, INC. | $33.25 | 2025 | Gvoke Hypopen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $30.04 | 2024-2025 | Korlym |
| Harmony Biosciences LLC | $15.83 | 2025 | |
| Bridgebio Pharma, INC. | $14.74 | 2025 | Attruby |
| Gilead Sciences, INC. | $14.07 | 2022 | |
| Abbvie INC. | $13.60 | 2021 | |
| Global Blood Therapeutics, INC. | $13.45 | 2021 | |
| Boston Scientific Corporation | $12.61 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.13 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vedat Obuz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.